Press-release for stocks publishing date 2021 - 05

Prices are updated after-hours

ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV
Published: 2021-05-04 (Crawled : 13:00) - biospace.com/
PFE | News 4 | $26.27 -0.19% -0.15% 23M

| -34.04% | O: 0.43% H: 0.43% C: -0.13%
GSK | News | $40.86 -0.92% -0.15% 1.7M

| 8.47% | O: -0.19% H: 0.29% C: -0.27%
new drug fda drug hiv submission application

PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS
Published: 2021-05-04 (Crawled : 12:00) - biospace.com/
VTRS | News A | $11.55 1.67% 1.65% 7.2M

| -14.44% | O: -0.07% H: 1.11% C: -0.67%
PFE | News 4 | $26.27 -0.19% -0.15% 23M

| -34.04% | O: 0.43% H: 0.43% C: -0.13%
LLY | News | $732.2 -1.81% 0.18% 2.1M

| 304.59% | O: 0.87% H: 1.36% C: 0.36%
BNTX | News | $88.18 -0.35% -0.35% 280K

| -57.83% | O: 1.72% H: 0.31% C: -16.76%
results report

Astellas' XTANDI™ (enzalutamide) Approved by European Commission for Men with Metastatic Hormone-Sensitive Prostate Cancer
Published: 2021-05-04 (Crawled : 07:00) - prnewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M

| -34.04% | O: 0.43% H: 0.43% C: -0.13%
europe prostate cancer cancer hormone approval

62%

38%

CSSE 4 | $0.4323 183.85% 64.77% 220M

BOF | $1.99 70.09% 41.21% 110M

ILAG | $0.51 6.03% 40.62% 1.7M

LICN | $0.941 68.04% 40.49% 15M

AMST | $3.31 65.5% 39.58% 70M

MTC | $3.615 61.38% 38.04% 9.3M

WIMI | $1.15 58.53% 36.92% 19M

AIH | $0.45 12.5% 30.92% 320K

MULN | News | $3.78 38.46% 27.78% 13M

RILY | $29.86 37.48% 27.26% 12M

Save your searches and get alerts when important news are released.